Belimumab: Targeted therapy for lupus

International Journal of Rheumatic Diseases

Volumn 16, Issue 1, 2013, Pages 4-13

  Chugh, Preeta K ^a   Kalra, Bhupinder S ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Autoimmune disease; B lymphocyte stimulator; Belimumab; Benlysta; Lupus; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; BELIMUMAB; PLACEBO;

ARTHRALGIA; DIARRHEA; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; NAUSEA; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET ORGAN; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; B-CELL ACTIVATING FACTOR; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84874374884     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185x.12002     Document Type: Review

References (30)

1. Centres for Disease Control and Prevention. Spotlight - Advancing our Epidemiologic Understanding of Lupus. (http://www.cdc.gov/arthritis/resources/spotlights/advancing.htm.) Accessed June 15, 2011.
2. Griffiths B, Mosca M, Gordon C (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19, 685-708.
3. Merrill JT (2009) Clinical trials for lupus - are we there yet? Bull NYU Hosp Jt Dis 67, 267-70.
4. Merrill JT, Neuwelt CM, Wallace DJ et al. (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62, 222-33.
5. Furie RA, Looney JR, Rovin B et al. (2009) Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum 60, 429.
6. Navarra SV, Guzmán RM, Gallacher AE et al. (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721-31.
7. Furie R, Petri M, Zamani O et al. (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63, 3918-30.
8. Stohl W, Hiepe F, Latinis KM et al. (2012) Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum Jan 24, 2328-37.
9. US Food and Drug Administration. FDA labelling information - Benlysta. (http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125370s0000lbl.pdf.) Accessed June10, 2011.
10. EPAR summary for the public. European Medicines Agency; 2011. (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002015/WC500110153.pdf). Accessed April 3, 2012. Last updated in 07-2011.
11. Treml JF, Hao Y, Stadanlick JE, Cancro MP (2009) The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 53, 1-16.
12. Moore PA, Belvedere O, Orr A et al. (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285, 260-3.
13. Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9, 491-502.
14. Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44, 1313-9.
15. Petri M, Stohl W, Chatham W et al. (2008) Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 58, 2453-9.
16. (2010) Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B. Drugs R D 10, 55-65.
17. Ramanujam M, Davidson A (2008) BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? Immunol Rev 223, 156-74.
18. Halpern WG, Lappin P, Zanardi T et al. (2006) Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 1, 586-99.
19. Furie R, Stohl W, Ginzler EM et al. (2008) Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 10, R109.
20. Wallace DJ, Stohl W, Furie RA et al. (2009) A phase II, randomized, double- blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61, 1168-78.
21. Petri M, Buyon J, Kim M (1999) Classification and definition of major flares in SLE clinical trials. Lupus 8, 685-91.
22. Merrill JT, Wallace DJ, Furie RA et al. (2010) Five-year experience with belimumab, a BLyS-specific inhibitor, in patients with Systemic Lupus Erythematosus (SLE). [abstract] Arthritis Rheum 62(Suppl.10), 1457.
23. Furie RA, Petri MA, Wallace DJ et al. (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 61, 1143-51.
24. BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia. (http://clinicaltrials.gov/ct2/show/NCT01597622?term=belimumab&recr=Open&no_unk=Y&rank=8) Accessed May 17, 2012.
25. A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia (NCT01345253). (http://clinicaltrials.gov/ct2/show/NCT01345253?cond=%22Systemic+Lupus+Erythematosus%22&rank=17) Accessed June 10, 2011.
26. A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) (BLISS-SC).(http://clinicaltrials.gov/ct2/show/NCT01484496?term=belimumab&recr=Open&no_unk=Y&rank=3) Accessed May 17, 2012.
27. A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE). (http://clinicaltrials.gov/ct2/show/NCT01597492?term=belimumab&rank=10) Accessed May 17, 2012.
28. Benlysta Pregnancy Registry. (http://clinicaltrials.gov/ct2/show/NCT01532310?term=belimumab&recr=Open&no_unk=Y&rank=4). Accessed May 17, 2012.
29. Clinicaltrials.gov, A service of the U.S. National Institutes of Health. (http://clinicaltrials.gov/ct2/results?term=belimumab) Accessed June 1, 2012.
30. Chugh PK (2012) Lupus: novel therapies in clinical development. Eur J Intern Med 23, 212-8.